ME01926B - 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat - Google Patents
6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleatInfo
- Publication number
- ME01926B ME01926B MEP-2014-154A MEP15414A ME01926B ME 01926 B ME01926 B ME 01926B ME P15414 A MEP15414 A ME P15414A ME 01926 B ME01926 B ME 01926B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- dihydro
- oxy
- pentyl
- purin
- Prior art date
Links
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 7
- LFMPVTVPXHNXOT-HNNXBMFYSA-N 6-amino-2-[(2s)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7h-purin-8-one Chemical compound C12=NC(O[C@@H](C)CCC)=NC(N)=C2NC(=O)N1CCCCCN1CCCCC1 LFMPVTVPXHNXOT-HNNXBMFYSA-N 0.000 claims 6
- 208000026935 allergic disease Diseases 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30301010P | 2010-02-10 | 2010-02-10 | |
| PCT/EP2011/051830 WO2011098452A1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| EP11709025.8A EP2534149B1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01926B true ME01926B (me) | 2015-05-20 |
Family
ID=43836817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2014-154A ME01926B (me) | 2010-02-10 | 2011-02-08 | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8703754B2 (enExample) |
| EP (1) | EP2534149B1 (enExample) |
| JP (1) | JP5922587B2 (enExample) |
| KR (1) | KR101773541B1 (enExample) |
| CN (1) | CN102753553B (enExample) |
| AU (1) | AU2011214468B2 (enExample) |
| BR (1) | BR112012018904A2 (enExample) |
| CA (1) | CA2786973C (enExample) |
| DK (1) | DK2534149T3 (enExample) |
| EA (1) | EA021048B1 (enExample) |
| ES (1) | ES2525826T3 (enExample) |
| HR (1) | HRP20141258T1 (enExample) |
| IL (1) | IL220845A (enExample) |
| ME (1) | ME01926B (enExample) |
| MX (1) | MX2012009316A (enExample) |
| PL (1) | PL2534149T3 (enExample) |
| PT (1) | PT2534149E (enExample) |
| RS (1) | RS53745B1 (enExample) |
| SG (1) | SG182471A1 (enExample) |
| SI (1) | SI2534149T1 (enExample) |
| SM (1) | SMT201400196B (enExample) |
| WO (1) | WO2011098452A1 (enExample) |
| ZA (1) | ZA201205995B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
| US9744183B2 (en) | 2009-07-06 | 2017-08-29 | Wave Life Sciences Ltd. | Nucleic acid prodrugs and methods of use thereof |
| NO2491035T3 (enExample) | 2009-10-22 | 2018-01-27 | ||
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| RU2014105311A (ru) | 2011-07-19 | 2015-08-27 | Уэйв Лайф Сайенсес Пте. Лтд. | Способы синтеза функционализованных нуклеиновых кислот |
| AU2012289042A1 (en) * | 2011-07-22 | 2014-03-13 | Glaxosmithkline Llc | Composition |
| BR112015000723A2 (pt) * | 2012-07-13 | 2017-06-27 | Shin Nippon Biomedical Laboratories Ltd | adjuvante de ácido nucléico quiral |
| KR102712879B1 (ko) | 2012-07-13 | 2024-10-04 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PT2872485T (pt) | 2012-07-13 | 2021-03-05 | Wave Life Sciences Ltd | Grupo auxiliar assimétrico |
| UA114109C2 (xx) | 2012-08-24 | 2017-04-25 | Піразолопіримідинові сполуки | |
| US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
| US9540383B2 (en) | 2012-11-20 | 2017-01-10 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
| ES2944885T3 (es) * | 2014-08-29 | 2023-06-26 | Corium Pharma Solutions Inc | Matriz de microestructuras para administración de agentes activos |
| CN107108628A (zh) * | 2014-11-13 | 2017-08-29 | 葛兰素史密丝克莱恩生物有限公司 | 可用于治疗变应性疾病或其它炎性病症的腺嘌呤衍生物 |
| US12130267B2 (en) * | 2018-11-28 | 2024-10-29 | Shimadzu Corporation | Analyzing method for azo compound |
| KR20250106231A (ko) | 2023-12-29 | 2025-07-09 | (주)셀트리온 | 안정한 약제학적 제제 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US5569450A (en) | 1993-03-17 | 1996-10-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| IL145071A0 (en) | 1999-12-27 | 2002-06-30 | Japan Tobacco Inc | Fused ring compounds and pharmaceutical compositions containing the same |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| CN1267446C (zh) | 2001-01-22 | 2006-08-02 | 默克公司 | 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物 |
| KR20030093248A (ko) | 2001-03-19 | 2003-12-06 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제 |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
| CA2481502A1 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| AR041816A1 (es) | 2002-10-24 | 2005-06-01 | Glaxo Group Ltd | Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo |
| WO2004055011A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| DE60322423D1 (de) | 2002-12-13 | 2008-09-04 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten |
| US7531661B2 (en) | 2002-12-13 | 2009-05-12 | Smithkline Beecham Corporation | Indane compounds as CCR5 antagonists |
| AU2003297048A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| ATE384724T1 (de) | 2002-12-13 | 2008-02-15 | Smithkline Beecham Corp | Cyclopropylverbindungen als ccr5 antagonisten |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| ES2431314T3 (es) | 2004-02-20 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Inhibidores de polimerasa vírica |
| KR20070011501A (ko) | 2004-04-28 | 2007-01-24 | 애로우 쎄라퓨틱스 리미티드 | 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체 |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EA012605B1 (ru) | 2004-08-18 | 2009-10-30 | Пфайзер Инк. | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с и композиции и способы лечения с их использованием |
| WO2006026394A2 (en) | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Method of eliciting an immune response against hiv |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| NZ563866A (en) | 2005-05-09 | 2011-03-31 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
| DK2132209T3 (da) * | 2007-03-19 | 2014-04-14 | Astrazeneca Ab | 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7) |
| PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| US8777708B2 (en) | 2008-06-27 | 2014-07-15 | Microsoft Corporation | Targeting control in a simulated environment |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
-
2011
- 2011-02-08 EA EA201290631A patent/EA021048B1/ru not_active IP Right Cessation
- 2011-02-08 JP JP2012552369A patent/JP5922587B2/ja active Active
- 2011-02-08 BR BR112012018904-2A patent/BR112012018904A2/pt not_active IP Right Cessation
- 2011-02-08 AU AU2011214468A patent/AU2011214468B2/en not_active Ceased
- 2011-02-08 RS RS20150005A patent/RS53745B1/sr unknown
- 2011-02-08 SI SI201130364T patent/SI2534149T1/sl unknown
- 2011-02-08 SG SG2012051140A patent/SG182471A1/en unknown
- 2011-02-08 WO PCT/EP2011/051830 patent/WO2011098452A1/en not_active Ceased
- 2011-02-08 HR HRP20141258AT patent/HRP20141258T1/hr unknown
- 2011-02-08 ME MEP-2014-154A patent/ME01926B/me unknown
- 2011-02-08 EP EP11709025.8A patent/EP2534149B1/en active Active
- 2011-02-08 PL PL11709025T patent/PL2534149T3/pl unknown
- 2011-02-08 CA CA2786973A patent/CA2786973C/en not_active Expired - Fee Related
- 2011-02-08 DK DK11709025.8T patent/DK2534149T3/da active
- 2011-02-08 PT PT117090258T patent/PT2534149E/pt unknown
- 2011-02-08 US US13/578,020 patent/US8703754B2/en not_active Expired - Fee Related
- 2011-02-08 MX MX2012009316A patent/MX2012009316A/es active IP Right Grant
- 2011-02-08 ES ES11709025.8T patent/ES2525826T3/es active Active
- 2011-02-08 CN CN201180009082.0A patent/CN102753553B/zh not_active Expired - Fee Related
- 2011-02-08 KR KR1020127023687A patent/KR101773541B1/ko not_active Expired - Fee Related
-
2012
- 2012-07-10 IL IL220845A patent/IL220845A/en not_active IP Right Cessation
- 2012-08-08 ZA ZA2012/05995A patent/ZA201205995B/en unknown
-
2014
- 2014-12-30 SM SM201400196T patent/SMT201400196B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012009316A (es) | 2012-09-12 |
| KR20120135408A (ko) | 2012-12-13 |
| CA2786973C (en) | 2018-04-10 |
| BR112012018904A2 (pt) | 2020-09-01 |
| SMT201400196B (it) | 2015-01-15 |
| CA2786973A1 (en) | 2011-08-18 |
| AU2011214468A1 (en) | 2012-08-09 |
| JP2013519645A (ja) | 2013-05-30 |
| JP5922587B2 (ja) | 2016-05-24 |
| KR101773541B1 (ko) | 2017-08-31 |
| CN102753553B (zh) | 2016-03-30 |
| IL220845A (en) | 2016-08-31 |
| US20120308609A1 (en) | 2012-12-06 |
| HRP20141258T1 (hr) | 2015-02-27 |
| DK2534149T3 (da) | 2015-01-05 |
| PL2534149T3 (pl) | 2015-03-31 |
| ES2525826T3 (es) | 2014-12-30 |
| RS53745B1 (sr) | 2015-06-30 |
| EA021048B1 (ru) | 2015-03-31 |
| EP2534149A1 (en) | 2012-12-19 |
| SG182471A1 (en) | 2012-08-30 |
| PT2534149E (pt) | 2014-12-23 |
| SI2534149T1 (sl) | 2015-02-27 |
| CN102753553A (zh) | 2012-10-24 |
| ZA201205995B (en) | 2014-01-29 |
| EA201290631A1 (ru) | 2013-03-29 |
| WO2011098452A1 (en) | 2011-08-18 |
| AU2011214468B2 (en) | 2015-05-28 |
| EP2534149B1 (en) | 2014-10-15 |
| US8703754B2 (en) | 2014-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01926B (me) | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat | |
| ME02274B (me) | DERIVATI PURINA ZA UPOTREBU U LEČENJU ALERGIJSKIH, INFLAMATORNIH l INFEKTIVNIH BOLESTI | |
| JP2013519645A5 (enExample) | ||
| BR112014001798A2 (pt) | compostos de tetraciclina 9-aminometila substituídos | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| JP2013542247A5 (enExample) | ||
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| ME02547B (me) | Inhibitori hepatitis c virusa | |
| PH12019502052A1 (en) | Hepatitis b virus surface antigen inhibitor | |
| HRP20171512T1 (hr) | Derivati betulina | |
| RU2015117251A (ru) | Новые соединения | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| NO20063693L (no) | Forbindelse og metode for anvendelse | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| JP2010270124A5 (enExample) | ||
| JP2014521735A5 (enExample) | ||
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| WO2012125926A3 (en) | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | |
| EP2581376A4 (en) | MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF | |
| ITMI20020808A1 (it) | Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione | |
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| CO6331429A2 (es) | Derivados de 5-(4-metanosulfonil-fenil)-tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas | |
| RU2017102043A (ru) | Новое соединение (ks513), выделенное из pseudolysimachion rotundum var. subintegrum, композиция, содержащая указанное соединение в качестве активного ингредиента, для предотващения или лечения аллергического заболевания, воспалительного заболевания, астмы или хронической обструктивной болезни легких и их применение | |
| Datta | Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase Ⅰ trial | |
| CY1116091T1 (el) | Μηλεϊνικη 6-αμινο-2-{[(1s)-1-μεθυλβουτυλ]οξυ}-9-[5-(1-πιπεριδινυλ)πεντυλ]-7,9-διυδρο-8η-πουριν-8-ονη |